Third MDoutlook post-ASCO QP released – GI Cancers

Following ASCO, we have surveyed our global MDoutlook network of over 62,000 cancer treaters. By pulsing the largest database of cancer providers in the world, Arcas is the only organization that can present you the clinical impact of new data on cancer therapies and clinical drivers with robustness and detail.

Focusing on key new data presented in Melanoma, Lung Cancer, Renal Cell Carcinoma, Prostate Cancer, Colorectal Cancer and Hepatocellular Carcinoma, we are distributing the results in separate reports. Based on a total response of more than 400 cancer treaters from now 27 countries, we are proud to present our analysis on the first four disease areas:
* MDoutlook ASCO 2012 QP – GI Cancers
* MDoutlook ASCO 2012 QP – NSCLC+RCC
* MDoutlook ASCO 2012 QP – Melanoma

MDoutlook activities are predicated on 3 critical principles: 1) Relevant and accurate insight directly from pre-validated treaters; 2) Robust coverage and 3) Rapid response. Insight is presented in reports that can be shared directly with senior management, and intelligence is enhanced by the review and feedback from key ThoughtLeaders in each disease covered.

We continue our collaboration with our friends at Oncology Business Review (OBR) for distribution of this report; their Editor’s Blog has a copy of the GI Cancer results published today.

If you have any questions or would like to discuss how MDoutlook can support your oncology intelligence needs, please contact me directly.

Regards,
Jan Heybroek
President, The Arcas Group